diflunisal has been researched along with Cardiomyopathies in 10 studies
Diflunisal: A salicylate derivative and anti-inflammatory analgesic with actions and side effects similar to those of ASPIRIN.
diflunisal : An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position.
Cardiomyopathies: A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Diflunisal was well-tolerated in both the ATTRm- and ATTRwt-CA populations." | 5.48 | Diflunisal tolerability in transthyretin cardiac amyloidosis: a single center's experience. ( Donnelly, JP; Hanna, M; Ikram, A; Samaras, C; Sperry, BW; Valent, J, 2018) |
| " Many of these therapies are older medications being given new roles such as mexiletine for Brugada syndrome and diflunisal for transthyretin amyloid cardiomyopathy." | 4.95 | Therapeutic Strategies Targeting Inherited Cardiomyopathies. ( Tang, WHW; Varian, K, 2017) |
| "Diflunisal is an approved non-steroidal anti-inflammatory drug that stabilizes TTR, with limited data available regarding effects on cardiac structure and function." | 1.56 | Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis. ( Berk, JL; Connors, LH; Fox, J; Gopal, DM; Hellawell, J; Lohrmann, G; Maurer, MS; Mussinelli, R; Pipilas, A; Ruberg, FL; Siddiqi, OK; Vellanki, N, 2020) |
| "Diflunisal was well-tolerated in both the ATTRm- and ATTRwt-CA populations." | 1.48 | Diflunisal tolerability in transthyretin cardiac amyloidosis: a single center's experience. ( Donnelly, JP; Hanna, M; Ikram, A; Samaras, C; Sperry, BW; Valent, J, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 7 (70.00) | 2.80 |
| Authors | Studies |
|---|---|
| Villanueva, E | 1 |
| Carretero, M | 1 |
| Aguirre, MA | 1 |
| Negro, A | 1 |
| Belziti, CA | 1 |
| Posadas-Martínez, ML | 1 |
| Nucifora, EM | 1 |
| Baratta, S | 1 |
| Costabel, JP | 1 |
| Higa, C | 1 |
| Rivas, C | 1 |
| Fernández, A | 1 |
| Quiroga, A | 1 |
| Dumont, CA | 1 |
| Volberg, VI | 1 |
| Streitenberg, GM | 1 |
| Perez de Arenaza, D | 1 |
| Nuvolone, M | 1 |
| Girelli, M | 1 |
| Merlini, G | 1 |
| Lohrmann, G | 1 |
| Pipilas, A | 1 |
| Mussinelli, R | 1 |
| Gopal, DM | 1 |
| Berk, JL | 1 |
| Connors, LH | 1 |
| Vellanki, N | 1 |
| Hellawell, J | 1 |
| Siddiqi, OK | 2 |
| Fox, J | 1 |
| Maurer, MS | 3 |
| Ruberg, FL | 1 |
| Rubin, J | 1 |
| Nelson, LT | 1 |
| Paxman, RJ | 1 |
| Xu, J | 1 |
| Webb, B | 1 |
| Powers, ET | 1 |
| Kelly, JW | 1 |
| Sarswat, N | 1 |
| Benbrahim, M | 1 |
| Norman, K | 1 |
| Sanchorawala, V | 1 |
| Hughes, D | 1 |
| Varian, K | 1 |
| Tang, WHW | 1 |
| Ikram, A | 1 |
| Donnelly, JP | 1 |
| Sperry, BW | 1 |
| Samaras, C | 1 |
| Valent, J | 1 |
| Hanna, M | 1 |
| Castaño, A | 1 |
| Drachman, BM | 1 |
| Judge, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis[NCT06034405] | 1,663 participants (Anticipated) | Observational | 2023-09-30 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for diflunisal and Cardiomyopathies
| Article | Year |
|---|---|
Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy.
Topics: Amyloid; Amyloid Neuropathies, Familial; Cardiomyopathies; Diflunisal; Humans; Prealbumin | 2022 |
Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.
Topics: Amyloid Neuropathies, Familial; Amyloidosis; Arrhythmias, Cardiac; Benzoates; Benzoxazoles; Biopsy; | 2020 |
A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.
Topics: Amyloid Neuropathies, Familial; Animals; Benzoxazoles; Cardiomyopathies; Cardiovascular Agents; Difl | 2021 |
Therapeutic Strategies Targeting Inherited Cardiomyopathies.
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Brugada Syndrome; Cardiomyopathies; Diflunisal; Geneti | 2017 |
Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs.
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Biomarkers; Cardiomyopathies; Cyclooxygenase Inhibitor | 2015 |
5 other studies available for diflunisal and Cardiomyopathies
| Article | Year |
|---|---|
[Specific pharmacological treatment guide for transthyretin amyloid cardiomyopathy, 2021].
Topics: Amyloid Neuropathies, Familial; Benzoxazoles; Cardiomyopathies; Diflunisal; Doxycycline; Humans; Pre | 2022 |
Stabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac Amyloidosis.
Topics: Aged; Aged, 80 and over; Amyloid Neuropathies, Familial; Cardiomyopathies; Diflunisal; Female; Heart | 2020 |
Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma.
Topics: Amyloid; Amyloid Neuropathies, Familial; Benzoates; Benzoxazoles; Cardiomyopathies; Diflunisal; Huma | 2021 |
An Orphan Disease No More: Additional Treatment Options for Cardiac Amyloidosis.
Topics: Amyloidosis; Cardiomyopathies; Diflunisal; Heart Failure; Humans; Prealbumin; Rare Diseases | 2020 |
Diflunisal tolerability in transthyretin cardiac amyloidosis: a single center's experience.
Topics: Aged; Amyloidosis; Anti-Inflammatory Agents, Non-Steroidal; Cardiomyopathies; Diflunisal; Female; Hu | 2018 |